Press Release: ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025

Dow Jones
2024-12-10
   Sale of QVQ Holdings BV shares                 --      121 
--------------------------------------------  ------   ------ 
Net cash used in investing activities           (328)    (509) 
--------------------------------------------  ------   ------ 
Financing activities: 
   Proceeds on share issuance, net of 
   transaction costs                           1,507       -- 
   Repayment of leases                          (801)    (715) 
   Proceeds on debenture issuance, net 
   of transaction costs                        4,059       -- 
----------------------------------------      ------   ------ 
Net cash provided by (used in) financing 
 activities                                    4,765     (715) 
--------------------------------------------  ------   ------ 
Increase (decrease) in cash during the 
 period                                          370   (1,794) 
Foreign exchange                                (294)    (468) 
Cash -- beginning of the period                3,545    8,366 
--------------------------------------------  ------   ------ 
Cash -- end of the period                      3,621    6,104 
--------------------------------------------  ------   ------ 
Cash is comprised of: 
   Cash                                        3,534    6,017 
   Restricted cash                                87       87 
--------------------------------------------  ------   ------ 
                                               3,621    6,104 
    ----------------------------------------  ------   ------ 
Cash paid for interest                            --       -- 
Cash paid for income tax                          --       -- 
--------------------------------------------  ------   ------ 
 

View source version on businesswire.com: https://www.businesswire.com/news/home/20241210683224/en/

 
    CONTACT: 

Investor Relations Contact

investors@ipatherapeutics.com

 
 

(END) Dow Jones Newswires

December 10, 2024 08:30 ET (13:30 GMT)

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10